CN Patent

CN112584837A — 新方法

Assigned to Intra Cellular Therapies Inc · Expires 2021-03-30 · 5y expired

What this patent protects

本公开涉及包含游离形式或药学上可接受的盐形式的、任选地与一种或多种另外的治疗剂组合的卢美哌隆的固体口服剂型，其制备方法以及用于治疗或预防疾病的方法。

USPTO Abstract

本公开涉及包含游离形式或药学上可接受的盐形式的、任选地与一种或多种另外的治疗剂组合的卢美哌隆的固体口服剂型，其制备方法以及用于治疗或预防疾病的方法。

Drugs covered by this patent

Duragesic (fentanyl) · Johnson & Johnson (Janssen Pharmaceutica)

Patent Metadata

Patent number: CN112584837A
Jurisdiction: CN
Classification: —
Expires: 2021-03-30
Drug substance claim: No
Drug product claim: No
Assignee: Intra Cellular Therapies Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.